MedPath

The MS-LINK™ Outcomes Study

Completed
Conditions
Multiple Sclerosis
Registration Number
NCT04735406
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Brief Summary

The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction from the participant's electronic medical record (EMR) and other health information systems (for example, radiology). Participants will complete patient-reported outcomes (PROs) and other health-related information digitally. Participating participants will have access to their own data in an ongoing manner via a web-based Participant Portal.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2182
Inclusion Criteria
  • Participants willing and able to provide written informed consent
  • Participants willing to be contacted while participating in the study for recruitment into sub-studies that may be relevant to them
  • Participants willing and able to complete PROs on a monthly basis and document events of interest as they occur
  • Participants willing to participate in additional follow up at the site for at least three years
Exclusion Criteria
  • Unable to complete questionnaires in English
  • Unable to consistently access the Internet
  • Participants participating in interventional clinical drug trials at baseline

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Timed 25-Foot Walk TestBaseline up to 3 years
Wasson Health Confidence Scale ScoreBaseline up to 3 years
Number of Participants with Current Use of Disease-Modifying Therapies (DMT)Baseline up to 3 years
Expanded Disability Status Scale (EDSS) ScoreBaseline up to 3 years
Multiple Sclerosis Functional Composite (MSFC) ScoreBaseline up to 3 years
Number of Participants with History of FallBaseline up to 3 years
Patient-determined Disease Steps (PDDS) Scale ScoreBaseline up to 3 years
Work Productivity and Activity Impairment Questionnaire-Multiple Sclerosis (WPAI-MS) ScoreBaseline up to 3 years
Well-being of Participant Assessed by Physical Activity DiaryBaseline up to 3 years

Participants can opt-in to use the Patient Portal to track their well-being in up to 9 domains like Sleep, Mood, Pain, Exercise, Mobility, Wellness, Energy, Bladder Function, Leisure activities.

Patient Reported Outcomes Measurement Information System (PROMIS) Multiple Sclerosis (MS) Fatigue ScoreBaseline up to 3 years
Patient Reported Outcomes Measurement Information System (PROMIS) Multiple Sclerosis (MS) Physical Function ScoreBaseline up to 3 years
Patient Health Questionnaire 9-Item (PHQ9) ScoreBaseline up to 3 years
Number of Participants With Adherence to Treatment as Assessed by Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)Baseline up to 3 years
Occurrence of RelapsesBaseline up to 3 years
Occurrence of Multiple Sclerosis (MS) SymptomsBaseline up to 3 years
Number of Utilization of Healthcare Resources by ParticipantsBaseline up to 3 years
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScoreBaseline up to 3 years
Patient Reported Outcomes Measurement Information System (PROMIS) MS Cognitive Function ScoreBaseline up to 3 years
Health-related Quality of Life Assessed by Centers for Disease Control and Prevention Health-Related Quality of Life Measure (CDC HRQoL-14)Baseline up to 3 years
Number of Participants with Reasons for Discontinued Disease-Modifying Therapies (DMT)Baseline up to 3 years
Duration of Disease-Modifying Therapies (DMT) useBaseline up to 3 years
Number of Participants with Response to Health Priorities and GoalsBaseline up to 3 years

Responses of participants regarding concern of Multiple Sclerosis (MS) for next visit, priority and wellness goals, and how close they are completing the goal will be recorded.

Paced Auditory Serial Addition Test (PASAT) ScoreBaseline up to 3 years
Processing Speed Test (PST)Baseline up to 3 years
Number of Participants with Magnetic resonance imaging (MRI) HistoryBaseline up to 3 years
Number of Participants with Adverse Events of InterestBaseline up to 3 years
Number of Participants with Symptoms of Coronavirus (COVID)Baseline up to 3 years
Symbol Digit Modalities Test (SDMT)Baseline up to 3 years
9-Hole Peg Test (9HPT) ScoreBaseline up to 3 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

The Oklahoma Medical Research Foundation

🇺🇸

Oklahoma City, Oklahoma, United States

Alabama Neurology Associates

🇺🇸

Birmingham, Alabama, United States

Atlanta Neuroscience Institute

🇺🇸

Atlanta, Georgia, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Memorial healthcare

🇺🇸

Owosso, Michigan, United States

University of Texas Health

🇺🇸

San Antonio, Texas, United States

Georgetown University

🇺🇸

Washington, District of Columbia, United States

University of Nebraska medical Center

🇺🇸

Omaha, Nebraska, United States

The University of Texas of Austin

🇺🇸

Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath